Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and…
<!-- Name:DistributionId Value:8782894 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
Browsing Tag
Urticaria
Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases,…
REDWOOD CITY, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies and stem cell transplant conditioning agents…
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible…
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID -- Evidence of clinical activity observed; full data set to be presented at upcoming scientific…
Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic…
SAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has…
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic…
-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile--Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week 12 and 75.1% at week 8 in the 3 mg/kg…
Chronic Spontaneous Urticaria Responds Quickly to BTK Inhibitor
BOSTON -- A form of chronic hives improved quickly and significantly in response to treatment with a novel Bruton's tyrosine kinase (BTK) inhibitor, a multicohort dose-finding study…
Dupilumab May Help in Tough-to-Treat Chronic Spontaneous Urticaria
PHOENIX -- Patients who received add-on dupilumab (Dupixent) treatment for chronic spontaneous urticaria (CSU) had reduced symptoms and experienced less itchiness, a phase III trial…
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the…
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with…
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible…
- 95% complete response rate after single dose of CDX-0159 -- Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief -- Median duration of response 77+ days in Cold Urticaria and 57+ days in…
A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline |…
Los Angeles, June 08, 2021 (GLOBE NEWSWIRE) -- A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline | Insights by DelveInsight For the treatment of Chronic Spontaneous Urticaria, there are…